MAPK1 and non-small cell lung carcinoma: For example, it is shown that up-regulation of OPN and integrin αVβ3 contributes to acquired resistance to gefitinib, by activating the downstream FAK/Akt/Erk pathway in NSCLC cells in vitro [83].